Rockland-based Pfizer and BioNTech submitted data to the Food and Drug Administration Tuesday on their COVID-19 vaccine trials in children ages 5-11.

The FDA is expected to take several weeks to analyze data.

MORE: Search for a Cure

The company announced positive results from a pivotal trial on Sept. 20, 2021.

In the trial, which included 2,268 participants 5 to 11 years of age, the vaccine demonstrated a favorable safety profile and elicited robust neutralizing antibody responses using a smaller two-dose regimen.

These results were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age who were immunized with a larger dose.

Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-reviewed publication.

Right now, the vaccine is available to anyone 12 and up. The state has already implemented mandatory mask mandates in schools and is requiring either a vaccination or weekly negative test for faculty and staff.

According to the state's COVID 19 report card, the Mid-Hudson region ranks fourth highest in the state for COVID cases among students, with just under 1,100 cases since Sept. 13.